Johnson and Johnson just raised guidance while absorbing nine-figure litigation charges, and the stock is still near levels that have historically rewarded patient buyers. Whether the talc courtroom drama is drowning out a rare…
Every serious AI chip on earth runs through one foundry, yet most investors are still sleeping on the infrastructure play hiding in plain sight. Here is why a recent macro selloff turned into a…
Two defense giants are betting on opposite sides of naval warfare, and one of them just posted negative free cash flow while the other is sitting on nearly two billion dollars of it. The…
Two tech titans sit within striking distance of each other at the top of the market, but their growth engines could not be more different. Which one deserves your attention before Apple's July 30…
Pfizer and Amgen both grew revenue last quarter at nearly the same pace, but the engines driving that growth point toward two very different futures in oncology. One company is collecting cash from proven…
Meta and Palantir both crushed Q1 expectations, but their valuations now live in completely different universes. The case for owning one and merely renting the other comes down to a single uncomfortable question about…
Google is quietly building silicon that threatens to cut NVIDIA out of its own customers' data centers, and the latest earnings from both companies reveal just how close that collision has become.
Walmart and Costco both just posted quarters that screamed safe haven, but their paths to getting there look nothing alike, and only one of them is rebuilding its cost structure from the ground up.
Abbott is down nearly 23% this year while Pfizer dangles a 7% yield, and both just beat Q1 estimates. One of these discounts is a genuine buying opportunity and the other is a slow-moving…
Broadcom just posted 143% AI revenue growth, yet its stock shed a quarter of its value in a single month while a founder quietly dumped over a million shares. The hyperscaler quietly disintermediating its…
Wall Street sees a sluggish legacy software company and keeps selling. One investor sees something else buried in the pipeline data, and keeps hitting buy on every red day.
Most AI investments force a choice between owning the infrastructure and cashing in on the product. One company has quietly collapsed that tradeoff in a way that changes the math on every other position…
While retail traders rush back into a stock priced like a lottery ticket, one overlooked mega-cap is quietly printing record cash flow and beating earnings estimates by double digits. The valuation gap between hype…
California just rewrote its EV subsidy rules in a way that shuts Tesla out and hands Rivian a channel its rival cannot touch, and the timing could not be more consequential for R2 deliveries.
Both Johnson and Johnson and Coca-Cola just beat earnings and both are pulling in capital fleeing tech, but only one of them earns its premium valuation in a world where pricing tailwinds can reverse…
Every time Wall Street panics over Amazon's massive capital spending tab, one investor hits the buy button again. Here is the contrarian case that the loudest critics are confusing a bill for a bet…
Both KDP and Coca-Cola just beat Q1 estimates, but one is breaking itself apart while the other defends a fortress, and the valuation gap between them tells a story that income investors may be…
Both Meta and NVIDIA delivered blowout quarters on the same AI wave, yet investors treated the two stocks very differently this summer. One company quietly flipped its biggest cost line into a potential revenue…
Microsoft has fallen 20% this year while its AI business accelerates at a triple-digit clip and its commercial backlog swells past half a trillion dollars, which raises an uncomfortable question about whether the market…
Broadcom and NVIDIA both crushed their latest earnings, but the gap between them is widening in ways the headline numbers hide. One company carries a timing advantage, a marquee customer anchor, and an AI…
